



ALK achieves general reimbursement for GRAZAX® in Spain

November 21, 2008

The Spanish authorities today announced that they have finalized the evaluation of ALK's application for price and reimbursement of the company's tablet based vaccine against grass pollen allergy with a positive outcome. GRAZAX® will now be eligible for general, national reimbursement on level with other pharmaceutical products in Spain. The decision, which comes earlier than anticipated, enables a launch of GRAZAX® for adults in Spain in due time ahead of the 2009 grass pollen season.

This announcement does not change ALK's financial outlook for 2008.

ALK-Abelló A/S

Jens Bager
President & CEO

For further information please contact:
Jens Bager, President and CEO, tel. +45 4574 7576

Investor Relations: Per Plotnikof, tel +45 4574 7527, mobile +45 2261 2525
Press: Jacob Frische, tel +45 4574 7551, mobile +45 2224 7551